Investigational Site Number : 643003
Novosibirsk 630087
0 studies enrolling now · 1 studies all time
What they study most
Hematological Malignancy
Studies at this site
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
— Completed